Personal information

Keywords

Molecular Pharmacology, Protein-Protein Interactions, Peptide Therapeutics, Oncology

Activities

Collapse all

Employment (1)

University of Glasgow: Glasgow, Glasgow, GB

2021-03-01 to present | Research Fellow (College of Medical, Veterinary and Life Sciences)
Employment
Source: Self-asserted source
Connor Blair

Education and qualifications (1)

University of Glasgow: Glasgow, Glasgow, GB

2017-10-02 to 2021-03-01 | PhD - Molecular Pharmacology (Institute of Cardiovascular and Medical Sciences)
Qualification
Source: Self-asserted source
Connor Blair

Professional activities (1)

Interface - Scottish Knowledge Exchange Awards: Edinburgh, GB

2020-02-27 | Innovator of the Future
Distinction
Source: Self-asserted source
Connor Blair

Funding (6)

HGSP Company Creation: Peptide Therapeutics

2023-05 to 2024-12 | Grant
Scottish Enterprise (Glasgow, GB)
GRANT_NUMBER:

PS730591C
Source: Self-asserted source
Connor Blair

Lead optimisation of an allosteric c-RAF inhibitor peptide for the treatment of KRAS-driven pancreatic cancer

2023-05 to 2024-05 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER:

MR/X502807/1
Source: Self-asserted source
Connor Blair

Lead optimisation of an allosteric c-RAF inhibitor peptide for the treatment of KRAS-driven pancreatic cancer

2023-05 to 2024-05 | Grant
Engineering and Physical Sciences Research Council (London, GB)
GRANT_NUMBER:

EP/X525716/1
Source: Self-asserted source
Connor Blair

Inhibiting c-RAF Activity and Treating RAS-Driven Cancer

2022-05 to 2022-12 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER:

MC_PC_19039
Source: Self-asserted source
Connor Blair

HGSP Opportunity Qualification: Peptide Therapeutics

2021-10 to 2022-10 | Grant
Scottish Enterprise (Glasgow, GB)
Source: Self-asserted source
Connor Blair

Targeting SARS-CoV-2 viral entry mechanism: Developing novel peptide disrupters of the hACE2 - SARS-CoV-2 Spike Protein-Protein Interaction

2020-07 to 2021-04 | Award
Wellcome Trust (Glasgow, GB)
GRANT_NUMBER: 204820/Z/16/Z
Source: Self-asserted source
Connor Blair

Works (9)

MYPT1 is a non-canonical AKAP that tethers PKA to the MLCP signaling node

2023-04-27 | Preprint
DOI: 10.1101/2023.04.27.538407
Contributors: Jawad S Khalil; Paulo A. Saldanha; Connor M Blair; Jiayue Ling; Wei Ji; George S. Baillie; Khalid M Naseem; Leonid L Nikitenko; Francisco Rivero
Source: check_circle
Crossref

Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor

2022-08-28 | Preprint
DOI: 10.1101/2022.08.28.505448
Contributors: Alexandra D. Brown; Kathleen L. Vergunst; Makenzie Branch; Connor M. Blair; Denis J. Dupré; George S. Baillie; David N. Langelaan
Source: check_circle
Crossref

Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins

Journal of Molecular and Cellular Cardiology
2022-04 | Journal article
DOI: 10.1016/j.yjmcc.2022.01.001
Part of ISSN: 0022-2828
Source: Self-asserted source
Connor Blair

Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction

PLOS ONE
2021-11-18 | Journal article
DOI: 10.1371/journal.pone.0260283
Part of ISSN: 1932-6203
Source: Self-asserted source
Connor Blair

Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.

Peptide science (Hoboken, N.J.)
2021-01-08 | Journal article
DOI: 10.1002/pep2.24217
PMID: 33615115
PMC: PMC7883042
Source: Self-asserted source
Connor Blair

Fibrin Breakdown Assay.

Bio-protocol
2020-04-20 | Journal article
DOI: 10.21769/bioprotoc.3585
PMID: 33659554
PMC: PMC7842290
Source: Self-asserted source
Connor Blair

Measuring cAMP Specific Phosphodiesterase Activity: A Two-step Radioassay.

Bio-protocol
2020-04-05 | Journal article
DOI: 10.21769/bioprotoc.3581
PMID: 33659551
Source: Self-asserted source
Connor Blair

Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes.

Biochemical Society transactions
2019-10-01 | Journal article
DOI: 10.1042/bst20190252
PMID: 31506329
Source: Self-asserted source
Connor Blair

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - c-Raf.

BMC cancer
2019-03-25 | Journal article
DOI: 10.1186/s12885-019-5489-4
PMID: 30909892
PMC: PMC6434832
Source: Self-asserted source
Connor Blair

Peer review (1 review for 1 publication/grant)

Review activity for Journal of physiology and biochemistry. (1)
How many people are using ORCID?